

# **teaching\_material\_book**

Stefan Thoma

Invalid Date

# Table of contents

<b>Preface</b>	<b>3</b>
Who ist this for . . . . .	3
What will you learn . . . . .	3
How is it structured . . . . .	3
Where can you find more . . . . .	3
<b>1 Introduction</b>	<b>4</b>
1.1 Structure of teal apps . . . . .	4
1.1.1 Modules . . . . .	4
<b>2 Data app</b>	<b>6</b>
2.1 Setup . . . . .	6
2.2 Your first app . . . . .	20
2.3 Code structure . . . . .	20
2.4 init() . . . . .	21
2.4.1 modules . . . . .	23
2.5 Toy app . . . . .	24
2.6 Production app . . . . .	25
<b>3 efficacy</b>	<b>27</b>
<b>4 Summary</b>	<b>28</b>
<b>References</b>	<b>29</b>

# Preface

## Who ist this for

This tutorial is aimed at data scientists / analysts who want to write their first **teal** application. We expect you to already have some R experience and that you know what you want to achieve with the application. You do not need to know how to create a shiny application. The **teal** package aims to make the creation of (teal-specific) shiny applications relatively intuitive without the need to understand how shiny works exactly. Shiny knowledge is useful once you want to either modify an application, or write your own teal module from scratch.

## What will you learn

## How is it structured

All chapters in this book follow a common structure: First, the learning goals of a chapter is defined. We then go through the step-by-step process of using specific **teal** modules. In each chapter we combine what we learned into one code chunk with which we can create a functional teal application. As every **teal** app requires data, the app created in the introduction will be the fundamental building block of the apps in the subsequent chapters. In the *toy apps* created in each chapter you should be able to understand every line of code. The code for a more developed app (but built for the same purpose) and a deployed instance of that app is linked at the end of each chapter. What you learned in this chapter should give you a good understanding of how the more developed application works.

## Where can you find more

# 1 Introduction

At the end of this chapter you should be able to

- understand the structure and utility of `teal` apps
- understand the utility of `teal` apps
- determine whether `teal` apps are useful for *you*

## 1.1 Structure of teal apps

`teal` is a shiny-based modular framework. It provides an interactive user interface allowing users to customize tables and visualizations facilitating the exploration and analysis of clinical trial data. Dynamic analysis and display control, data filtering and code reproducibility are included in each module.

`teal` modules are laid out in three panels.

- The **Left Panel**, referred to as the encoding panel, includes elements used to adjust the output interactively.
- The **Center Panel**, referred to as the output panel, where the tables and visualizations are displayed.
- The **Right Panel**, referred to as the data filter panel, includes elements used to subset the data interactively.

The layout is pre-set within each module. However, user can decide overall tab order and nesting. See [?@fig-layout](#) for the typical `teal` app structure.

### 1.1.1 Modules

`teal` modules are modular building blocks for your `teal` app. They implement specific app functionalities, such as outlier exploration, data visualizations, and survival analysis. Although modules can be created from scratch, many `teal` modules have already been released and can be found in the following packages:




Figure 1.1: Typical teal app layout

- `teal.modules.general`: general modules for exploring relational/independent/CDISC data
- `teal.modules.clinical`: modules specific to CDISC data and clinical trial reporting
- `teal.modules.hermes`: modules for analyzing [MultiAssayExperiment](#) objects

are shiny modules built within the teal framework that specify analysis to be performed.

## 2 Data app

The App created at the end of this chapter will be the basic building block of all subsequent chapters in this book. The structure of the app code will remain consistent throughout the book — make sure you understand each line of code of the *toy* application at the end.

**At the end of this chapter you should be able to**

- understand the code structure of **teal** apps
- understand the workflow to create a **teal** app
- install and load the relevant packages
- write your own app that displays data

### 2.1 Setup

In this tutorial we will be working with realistic looking but simulated data.

```
if (!require("remotes")) install.packages("remotes")

# install teal
remotes::install_github("insightsengineering/teal@*release")

# install teal.modules.general
remotes::install_github("insightsengineering/teal.modules.general@*release")

# install teal.modules.hermes
remotes::install_github("insightsengineering/teal.modules.hermes@*release")

library(random.cdisc.data) # this package provides the data used
library(teal.data)
```

Loading required package: shiny

```
library(scda)
```

There are no scda.XXXX libraries installed, like scda.2022.  
Please install an scda database to take full advantage of the scda package.

```
library(teal.modules.general)
```

```
Loading required package: ggmosaic
```

```
Loading required package: ggplot2
```

```
Loading required package: shinyTree
```

```
Loading required package: teal
```

```
Loading required package: teal.transform
```

```
Loading required package: magrittr
```

```
You are using teal version 0.12.0
```

```
library(sparkline)
library(teal)
library(tidyverse)
```

```
-- Attaching packages ----- tidyverse 1.3.2 --
```

```
v tibble  3.1.8      v dplyr   1.0.10
v tidyr   1.2.1      v stringr 1.5.0
v readr   2.1.3      v forcats 0.5.2
v purrr   0.3.5
```

```
-- Conflicts ----- tidyverse_conflicts() --
```

```
x tidyr::extract() masks magrittr::extract()
x dplyr::filter()  masks stats::filter()
x dplyr::lag()     masks stats::lag()
x tidyr::replace_na() masks random.cdisc.data::replace_na()
x purrr::set_names() masks magrittr::set_names()
```

We first load two synthetic data sets. `random.cdisc.data::cads1` is a Subject Level Analysis Dataset (ADSL) with one record (row) per subject. The unique identifier per subject is stored in the variable `USUBJID`. According to [CDISC](#) the main purpose of ADSL is to provide a “(...) source for denominators for populations of interest, stratification variables, and other important subject subgroups”.

We can now load the three data-sets:

Data Structure for Adverse Event Analysis

```
ADSL <- random.cdisc.data::cads1
ADAE <- random.cdisc.data::cadae
ADTTE <- random.cdisc.data::cadtte
```

Data-set name	Explanation	Meaning
ADSL	Analysis data-set subject level	
ADAE	Analysis data-set for adverse events	
ADTTE	Analysis data-set for time to event	

Analysis data-set for time to event (efficacy).

```
map(list(ADSL, ADAE, ADTTE), summary)
```

```
[[1]]
```

STUDYID	USUBJID	SUBJID	SITEID
Length:400	Length:400	Length:400	Length:400
Class :character	Class :character	Class :character	Class :character
Mode :character	Mode :character	Mode :character	Mode :character

AGE	AGEU	SEX
Min. :20.00	YEARS:400	F:231
1st Qu.:29.00		M:169
Median :34.00		
Mean :34.88		
3rd Qu.:39.00		
Max. :69.00		

RACE

ETHNIC



ASIAN	:208	NOT REPORTED	: 27
BLACK OR AFRICAN AMERICAN	: 91	HISPANIC OR LATINO	: 48
WHITE	: 74	NOT HISPANIC OR LATINO	:308
AMERICAN INDIAN OR ALASKA NATIVE	: 25	UNKNOWN	: 17
MULTIPLE	: 1		
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER:	1		
(Other)	: 0		

COUNTRY	DTHFL	INVID	INVNAM
CHN :219	N:330	Length:400	Length:400
USA : 40	Y: 70	Class :character	Class :character
PAK : 31		Mode :character	Mode :character
BRA : 30			
NGA : 26			
RUS : 19			
(Other): 35			

ARM	ARMCD	ACTARM	ACTARMCD
A: Drug X :134	ARM A:134	A: Drug X :134	ARM A:134
B: Placebo :134	ARM B:134	B: Placebo :134	ARM B:134
C: Combination:132	ARM C:132	C: Combination:132	ARM C:132

TRT01P	TRT01A	TRT02P
A: Drug X :134	A: Drug X :134	A: Drug X :134
B: Placebo :134	B: Placebo :134	B: Placebo :134
C: Combination:132	C: Combination:132	C: Combination:132

TRT02A	REGION1	STRATA1	STRATA2	BMRKR1
A: Drug X :134	Africa : 26	A:122	S1:196	Min. : 0.1654
B: Placebo :134	Asia :268	B:135	S2:204	1st Qu.: 3.3552
C: Combination:132	Eurasia : 19	C:143		Median : 4.8392
	Europe : 9			Mean : 5.7628
	North America: 48			3rd Qu.: 7.4481
	South America: 30			Max. :21.3934

BMRKR2	ITTFL	SAFFL	BMEASIFL	BEP01FL	AEWITHFL	RANDDT
LOW :135	Y:400	Y:400	Y:203	Y:197	Y: 23	Min. :2019-02-22
MEDIUM:135			N:197	N:203	N:377	1st Qu.:2019-09-13
HIGH :130						Median :2020-02-16

Mean :2020-02-20  
 3rd Qu.:2020-08-14  
 Max. :2021-02-14

TRTSDTM  
 Min. :2019-02-24 12:09:18.68  
 1st Qu.:2019-09-17 17:51:52.18  
 Median :2020-02-18 15:58:51.68  
 Mean :2020-02-23 06:56:04.97  
 3rd Qu.:2020-08-18 00:04:25.18  
 Max. :2021-02-17 15:42:27.68

TRT01SDTM  
 Min. :2019-02-24 12:09:18.68  
 1st Qu.:2019-09-17 17:51:52.18  
 Median :2020-02-18 15:58:51.68  
 Mean :2020-02-23 06:56:04.97  
 3rd Qu.:2020-08-18 00:04:25.18  
 Max. :2021-02-17 15:42:27.68

TRT02SDTM  
 Min. :2021-02-11 23:06:46.68  
 1st Qu.:2021-02-17 12:40:58.18  
 Median :2021-07-16 23:30:14.68  
 Mean :2021-11-02 11:11:37.00  
 3rd Qu.:2022-08-01 22:21:01.18  
 Max. :2023-02-18 03:20:51.68  
 NA's :73

AP01SDTM  
 Min. :2019-02-24 12:09:18.68  
 1st Qu.:2019-09-17 17:51:52.18  
 Median :2020-02-18 15:58:51.68  
 Mean :2020-02-23 06:56:04.97  
 3rd Qu.:2020-08-18 00:04:25.18  
 Max. :2021-02-17 15:42:27.68

AP02SDTM  
 Min. :2021-02-11 23:06:46.68  
 1st Qu.:2021-02-17 12:40:58.18  
 Median :2021-07-16 23:30:14.68  
 Mean :2021-11-02 11:11:37.00  
 3rd Qu.:2022-08-01 22:21:01.18  
 Max. :2023-02-18 03:20:51.68

TRTEDTM  
 Min. :2022-02-12 04:55:58.68  
 1st Qu.:2022-02-17 18:30:10.18  
 Median :2022-07-17 05:19:26.68  
 Mean :2022-11-02 17:00:49.00  
 3rd Qu.:2023-08-02 04:10:13.18  
 Max. :2024-02-18 09:10:03.68  
 NA's :73

TRT01EDTM  
 Min. :2021-02-11 23:06:46.68  
 1st Qu.:2021-02-17 12:40:58.18  
 Median :2021-07-16 23:30:14.68  
 Mean :2021-11-02 11:11:37.00  
 3rd Qu.:2022-08-01 22:21:01.18  
 Max. :2023-02-18 03:20:51.68  
 NA's :73

TRT02EDTM  
 Min. :2022-02-12 04:55:58.68  
 1st Qu.:2022-02-17 18:30:10.18  
 Median :2022-07-17 05:19:26.68  
 Mean :2022-11-02 17:00:49.00  
 3rd Qu.:2023-08-02 04:10:13.18  
 Max. :2024-02-18 09:10:03.68  
 NA's :73

AP01EDTM  
 Min. :2021-02-11 23:06:46.68  
 1st Qu.:2021-02-17 12:40:58.18  
 Median :2021-07-16 23:30:14.68  
 Mean :2021-11-02 11:11:37.00  
 3rd Qu.:2022-08-01 22:21:01.18  
 Max. :2023-02-18 03:20:51.68  
 NA's :73

AP02EDTM  
 Min. :2022-02-12 04:55:58.68  
 1st Qu.:2022-02-17 18:30:10.18  
 Median :2022-07-17 05:19:26.68  
 Mean :2022-11-02 17:00:49.00  
 3rd Qu.:2023-08-02 04:10:13.18  
 Max. :2024-02-18 09:10:03.68

NA's :73		NA's :73	
EOSSTT	EOTSTT	EOSDT	EOSDY
COMPLETED :207	COMPLETED :207	Min. :2022-02-12	Min. : 369.0
DISCONTINUED:120	DISCONTINUED:120	1st Qu.:2022-02-17	1st Qu.: 868.0
ONGOING : 73	ONGOING : 73	Median :2022-07-17	Median :1096.0
		Mean :2022-11-02	Mean : 965.8
		3rd Qu.:2023-08-01	3rd Qu.:1096.0
		Max. :2024-02-18	Max. :1096.0
		NA's :73	NA's :73
DCSREAS	DTHDT		DTHCAUS
DEATH : 70	Min. :2022-02-14	ADVERSE EVENT : 26	
ADVERSE EVENT : 14	1st Qu.:2022-03-01	DISEASE PROGRESSION: 20	
PROTOCOL VIOLATION: 12	Median :2022-03-11	MISSING : 7	
LACK OF EFFICACY : 7	Mean :2022-03-13	LOST TO FOLLOW UP : 6	
PHYSICIAN DECISION: 7	3rd Qu.:2022-03-27	SUICIDE : 5	
(Other) : 10	Max. :2022-04-10	(Other) : 6	
NA's :280	NA's :330	NA's :330	
DTHCAT	LDDTHELD	LDDTHGR1	LSTALVDT
ADVERSE EVENT : 26	Min. : 1.0	<=30: 39	Min. :2022-02-14
OTHER : 24	1st Qu.:12.0	>30 : 31	1st Qu.:2022-03-15
PROGRESSIVE DISEASE: 20	Median :25.0	NA's:330	Median :2022-08-07
NA's :330	Mean :26.2		Mean :2022-11-23
	3rd Qu.:39.0		3rd Qu.:2023-08-21
	Max. :50.0		Max. :2024-03-07
	NA's :330		NA's :73
DTHADY	ADTHAUT	study_duration_secs	
Min. : 399.0	No : 10	Min. :63113904	
1st Qu.: 567.8	Yes : 47	1st Qu.:63113904	
Median : 765.5	NA's:343	Median :63113904	
Mean : 762.4		Mean :63113904	
3rd Qu.: 923.0		3rd Qu.:63113904	
Max. :1122.0		Max. :63113904	
NA's :330			

[[2]]

STUDYID	USUBJID	SUBJID	SITEID
Length:1934	Length:1934	Length:1934	Length:1934
Class :character	Class :character	Class :character	Class :character
Mode :character	Mode :character	Mode :character	Mode :character

	AGE	AGEU	SEX
Min.	:20.00	YEARS:1934	F:1174
1st Qu.	:29.00		M: 760
Median	:34.00		
Mean	:34.77		
3rd Qu.	:39.00		
Max.	:69.00		

	RACE	ETHNIC
ASIAN	:979	NOT REPORTED : 138
BLACK OR AFRICAN AMERICAN	:469	HISPANIC OR LATINO : 262
WHITE	:367	NOT HISPANIC OR LATINO:1470
AMERICAN INDIAN OR ALASKA NATIVE	:109	UNKNOWN : 64
MULTIPLE	: 6	
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER:	4	
(Other)	: 0	

	COUNTRY	DTHFL	INVID	INVNAM
CHN	:1061	N:1609	Length:1934	Length:1934
USA	: 207	Y: 325	Class :character	Class :character
BRA	: 156		Mode :character	Mode :character
PAK	: 137			
NGA	: 127			
RUS	: 97			
(Other):	149			

	ARM	ARMCD	ACTARM	ACTARMCD
A: Drug X	:609	ARM A:609	A: Drug X :609	ARM A:609
B: Placebo	:622	ARM B:622	B: Placebo :622	ARM B:622
C: Combination:	703	ARM C:703	C: Combination:703	ARM C:703

	TRT01P	TRT01A	TRT02P
A: Drug X	:609	A: Drug X :609	A: Drug X :659
B: Placebo	:622	B: Placebo :622	B: Placebo :647
C: Combination:	703	C: Combination:703	C: Combination:628

	TRT02A	REGION1	STRATA1	STRATA2	BMRKR1
A: Drug X	:625	Africa : 127	A:590	S1: 882	Min. : 0.1654
B: Placebo	:701	Asia :1273	B:661	S2:1052	1st Qu.: 3.3426

C: Combination:608	Eurasia	:	97	C:683	Median	:	5.0342
	Europe	:	31		Mean	:	5.8690
	North America:		250		3rd Qu.:		7.6002
	South America:		156		Max.	:	21.3934

BMRKR2	ITTFL	SAFFL	BMEASIFL	BEP01FL	AEWITHFL	RANDDT
LOW :664	Y:1934	Y:1934	Y: 932	Y:984	Y: 136	Min. :2019-02-22
MEDIUM:685			N:1002	N:950	N:1798	1st Qu.:2019-09-13
HIGH :585						Median :2020-02-17
						Mean :2020-02-22
						3rd Qu.:2020-08-21
						Max. :2021-02-09

TRTSDTM			TRTEDTM		
Min.	:2019-02-24	12:09:18.68	Min.	:2022-02-12	04:55:58.68
1st Qu.	:2019-09-16	20:21:14.68	1st Qu.	:2022-02-17	04:34:27.68
Median	:2020-02-21	17:10:24.68	Median	:2022-07-28	19:11:19.68
Mean	:2020-02-25	10:02:54.85	Mean	:2022-11-12	11:11:22.47
3rd Qu.	:2020-08-24	06:57:06.18	3rd Qu.	:2023-08-06	21:34:02.68
Max.	:2021-02-11	22:33:08.68	Max.	:2024-02-09	23:56:28.68
			NA's	:348	

TRT01SDTM			TRT01EDTM		
Min.	:2019-02-24	12:09:18.68	Min.	:2021-02-11	23:06:46.68
1st Qu.	:2019-09-16	20:21:14.68	1st Qu.	:2021-02-16	22:45:15.68
Median	:2020-02-21	17:10:24.68	Median	:2021-07-28	13:22:07.68
Mean	:2020-02-25	10:02:54.85	Mean	:2021-11-12	05:22:10.47
3rd Qu.	:2020-08-24	06:57:06.18	3rd Qu.	:2022-08-06	15:44:50.68
Max.	:2021-02-11	22:33:08.68	Max.	:2023-02-09	18:07:16.68
			NA's	:348	

TRT02SDTM			TRT02EDTM		
Min.	:2021-02-11	23:06:46.68	Min.	:2022-02-12	04:55:58.68
1st Qu.	:2021-02-16	22:45:15.68	1st Qu.	:2022-02-17	04:34:27.68
Median	:2021-07-28	13:22:07.68	Median	:2022-07-28	19:11:19.68
Mean	:2021-11-12	05:22:10.47	Mean	:2022-11-12	11:11:22.47
3rd Qu.	:2022-08-06	15:44:50.68	3rd Qu.	:2023-08-06	21:34:02.68
Max.	:2023-02-09	18:07:16.68	Max.	:2024-02-09	23:56:28.68
NA's	:348		NA's	:348	

AP01SDTM			AP01EDTM		
Min.	:2019-02-24	12:09:18.68	Min.	:2021-02-11	23:06:46.68
1st Qu.	:2019-09-16	20:21:14.68	1st Qu.	:2021-02-16	22:45:15.68
Median	:2020-02-21	17:10:24.68	Median	:2021-07-28	13:22:07.68
Mean	:2020-02-25	10:02:54.85	Mean	:2021-11-12	05:22:10.47
3rd Qu.	:2020-08-24	06:57:06.18	3rd Qu.	:2022-08-06	15:44:50.68

Max.	:2021-02-11 22:33:08.68	Max.	:2023-02-09 18:07:16.68
		NA's	:348
APO2SDTM		APO2EDTM	
Min.	:2021-02-11 23:06:46.68	Min.	:2022-02-12 04:55:58.68
1st Qu.	:2021-02-16 22:45:15.68	1st Qu.	:2022-02-17 04:34:27.68
Median	:2021-07-28 13:22:07.68	Median	:2022-07-28 19:11:19.68
Mean	:2021-11-12 05:22:10.47	Mean	:2022-11-12 11:11:22.47
3rd Qu.	:2022-08-06 15:44:50.68	3rd Qu.	:2023-08-06 21:34:02.68
Max.	:2023-02-09 18:07:16.68	Max.	:2024-02-09 23:56:28.68
NA's	:348	NA's	:348
EOSSTT		EOTSTT	EOSDT
COMPLETED	:1021	COMPLETED	:1021
DISCONTINUED	:565	DISCONTINUED	:565
ONGOING	:348	ONGOING	:348
		Min.	:2022-02-12
		1st Qu.	:2022-02-17
		Median	:2022-07-28
		Mean	:2022-11-11
		3rd Qu.	:2023-08-06
		Max.	:2024-02-09
		NA's	:348
		Min.	:369.0
		1st Qu.	:892.0
		Median	:1096.0
		Mean	:972.9
		3rd Qu.	:1096.0
		Max.	:1096.0
		NA's	:348
DCSREAS		DTHDT	DTHCAUS
DEATH	:325	Min.	:2022-02-14
ADVERSE EVENT	:81	1st Qu.	:2022-03-01
LACK OF EFFICACY	:44	Median	:2022-03-13
PROTOCOL VIOLATION	:39	Mean	:2022-03-14
PHYSICIAN DECISION	:34	3rd Qu.	:2022-03-29
(Other)	:42	Max.	:2022-04-09
NA's	:1369	NA's	:1609
		ADVERSE EVENT	:124
		DISEASE PROGRESSION	:101
		MISSING	:32
		LOST TO FOLLOW UP	:22
		SUICIDE	:20
		(Other)	:26
		NA's	:1609
DTHCAT		LDDTHELD	LDDTHGR1
ADVERSE EVENT	:124	Min.	:1.00
OTHER	:100	1st Qu.	:12.00
PROGRESSIVE DISEASE	:101	Median	:25.00
NA's	:1609	Mean	:26.98
		3rd Qu.	:40.00
		Max.	:50.00
		NA's	:1609
		<=30	:182
		>30	:143
		NA's	:1609
		Min.	:2022-02-14
		1st Qu.	:2022-03-16
		Median	:2022-08-12
		Mean	:2022-12-02
		3rd Qu.	:2023-08-29
		Max.	:2024-02-29
		NA's	:348
DTHADY	ADTHAUT	study_duration_secs	ASEQ
Min.	No : 38	Min.	:63113904
1st Qu.	Yes : 233	1st Qu.	:63113904
Median	NA's:1663	Median	:63113904
Mean		Mean	:63113904
3rd Qu.		3rd Qu.	:63113904
Max.		Max.	:63113904
NA's		Max.	:10.000
AESEQ		AETERM	AELLT
		AEDECOD	

Min.	: 1.000	trm B.2.2.3.1:217	llt B.2.2.3.1:217	dcd B.2.2.3.1:217
1st Qu.:	2.000	trm A.1.1.1.1:214	llt A.1.1.1.1:214	dcd A.1.1.1.1:214
Median	: 3.000	trm A.1.1.1.2:208	llt A.1.1.1.2:208	dcd A.1.1.1.2:208
Mean	: 3.954	trm D.2.1.5.3:208	llt D.2.1.5.3:208	dcd D.2.1.5.3:208
3rd Qu.:	6.000	trm B.2.1.2.1:193	llt B.2.1.2.1:193	dcd B.2.1.2.1:193
Max.	:10.000	trm D.1.1.4.2:185	llt D.1.1.4.2:185	dcd D.1.1.4.2:185
		(Other) :709	(Other) :709	(Other) :709

AEHLT		AEHLGT		AEBODSYS		AESOC		AESEV	
hlt A.1.1.1:422	hlgt A.1.1:422	cl A.1:422	cl A:422	MILD	:639				
hlt B.2.2.3:217	hlgt D.1.1:368	cl B.1:178	cl B:588	MODERATE	:752				
hlt D.2.1.5:208	hlgt B.2.2:217	cl B.2:410	cl C:348	SEVERE	:543				
hlt B.2.1.2:193	hlgt D.2.1:208	cl C.1:182	cl D:576						
hlt D.1.1.4:185	hlgt B.2.1:193	cl C.2:166							
hlt D.1.1.1:183	hlgt C.1.1:182	cl D.1:368							
(Other) :526	(Other) :344	cl D.2:208							
AESER		AEACN		AEREL		AEOUT		AESDTH	
N:1148	Length:1934	N:1017	Length:1934	N:1573	N:1627				
Y: 786	Class :character	Y: 917	Class :character	Y: 361	Y: 307				
	Mode :character		Mode :character						

AESDISAB	AESHOSP	AESLIFE	AESMIE	TRTEMFL	AECONTRT
N:1608	N:1584	N:1784	N:1494	: 1	N:1164
Y: 326	Y: 350	Y: 150	Y: 440	Y:1933	Y: 770

ASTDTM		AENDTM	
Min.	:2019-03-23 01:00:00.0	Min.	:2019-07-14 02:00:00.00
1st Qu.:	2020-09-13 14:00:00.0	1st Qu.:	2021-07-03 02:00:00.00
Median	:2021-05-16 14:00:00.0	Median	:2021-12-18 01:00:00.00
Mean	:2021-05-31 05:39:38.9	Mean	:2022-01-26 14:53:10.49
3rd Qu.:	2021-12-27 01:00:00.0	3rd Qu.:	2022-09-27 02:00:00.00
Max.	:2024-01-02 01:00:00.0	Max.	:2024-01-23 01:00:00.00

ASTDY		AENDY		LDOSEDTM		AETOXGR	
Min.	: 0.0	Min.	: 5.0	Min.	:2019-03-16 12:13:13.17	1:639	
1st Qu.:	215.2	1st Qu.:	511.0	1st Qu.:	2020-03-03 09:07:03.99	2:374	
Median	: 422.0	Median	: 709.5	Median	:2020-10-02 08:38:33.20	3:378	

Mean	: 461.3	Mean	: 701.7	Mean	:2020-10-11 01:17:57.76	4:182
3rd Qu.:	674.8	3rd Qu.:	941.0	3rd Qu.:	2021-03-23 07:46:41.46	5:361
Max.	:1095.0	Max.	:1097.0	Max.	:2023-09-25 18:45:44.75	

SMQ01NAM	SMQ02NAM	SMQ01SC	SMQ02SC
Length:1934	Length:1934	Length:1934	Length:1934
Class :character	Class :character	Class :character	Class :character
Mode :character	Mode :character	Mode :character	Mode :character

CQ01NAM	ANL01FL	AERELNST
Length:1934	: 348	CONCURRENT ILLNESS :576
Class :character	Y:1586	DISEASE UNDER STUDY:566
Mode :character	NONE	:218
	OTHER	:574

	AEACNOTH
MEDICATION	:353
NONE	:391
PROCEDURE/SURGERY	:793
SUBJECT DISCONTINUED FROM STUDY:	397

[[3]]

STUDYID	USUBJID	SUBJID	SITEID
Length:2000	Length:2000	Length:2000	Length:2000
Class :character	Class :character	Class :character	Class :character
Mode :character	Mode :character	Mode :character	Mode :character

AGE	AGEU	SEX
Min. :20.00	YEARS:2000	F:1155
1st Qu.:29.00		M: 845
Median :34.00		
Mean :34.88		



3rd Qu.:39.00  
 Max. :69.00

	RACE	ETHNIC
ASIAN	:1040	NOT REPORTED : 135
BLACK OR AFRICAN AMERICAN	: 455	HISPANIC OR LATINO : 240
WHITE	: 370	NOT HISPANIC OR LATINO:1540
AMERICAN INDIAN OR ALASKA NATIVE	: 125	UNKNOWN : 85
MULTIPLE	: 5	
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER:	5	
(Other)	: 0	

COUNTRY	DTHFL	INVID	INVNAM
CHN :1095	N:1650	Length:2000	Length:2000
USA : 200	Y: 350	Class :character	Class :character
PAK : 155		Mode :character	Mode :character
BRA : 150			
NGA : 130			
RUS : 95			
(Other): 175			

ARM	ARMCD	ACTARM	ACTARMCD
A: Drug X :670	ARM A:670	A: Drug X :670	ARM A:670
B: Placebo :670	ARM B:670	B: Placebo :670	ARM B:670
C: Combination:660	ARM C:660	C: Combination:660	ARM C:660

TRT01P	TRT01A	TRT02P
A: Drug X :670	A: Drug X :670	A: Drug X :670
B: Placebo :670	B: Placebo :670	B: Placebo :670
C: Combination:660	C: Combination:660	C: Combination:660

TRT02A	REGION1	STRATA1	STRATA2	BMRKR1
A: Drug X :670	Africa : 130	A:610	S1: 980	Min. : 0.1654
B: Placebo :670	Asia :1340	B:675	S2:1020	1st Qu.: 3.3552
C: Combination:660	Eurasia : 95	C:715		Median : 4.8392
	Europe : 45			Mean : 5.7628
	North America: 240			3rd Qu.: 7.4481
	South America: 150			Max. :21.3934

BMRKR2	ITTFL	SAFFL	BMEASIFL	BEP01FL	AEWITHFL	RANDDT
LOW :675	Y:2000	Y:2000	Y:1015	Y: 985	Y: 115	Min. :2019-02-22
MEDIUM:675			N: 985	N:1015	N:1885	1st Qu.:2019-09-13
HIGH :650						Median :2020-02-16
						Mean :2020-02-20
						3rd Qu.:2020-08-14
						Max. :2021-02-14

TRTSDDTM

Min. :2019-02-24 12:09:18.68

1st Qu.:2019-09-17 17:51:52.18

Median :2020-02-18 15:58:51.68

Mean :2020-02-23 06:56:04.97

3rd Qu.:2020-08-18 00:04:25.18

Max. :2021-02-17 15:42:27.68

TRT01SDTM

Min. :2019-02-24 12:09:18.68

1st Qu.:2019-09-17 17:51:52.18

Median :2020-02-18 15:58:51.68

Mean :2020-02-23 06:56:04.97

3rd Qu.:2020-08-18 00:04:25.18

Max. :2021-02-17 15:42:27.68

TRT02SDTM

Min. :2021-02-11 23:06:46.68

1st Qu.:2021-02-17 12:39:02.68

Median :2021-07-16 23:30:14.68

Mean :2021-11-02 11:11:37.00

3rd Qu.:2022-08-02 06:27:01.68

Max. :2023-02-18 03:20:51.68

NA's :365

AP01SDTM

Min. :2019-02-24 12:09:18.68

1st Qu.:2019-09-17 17:51:52.18

Median :2020-02-18 15:58:51.68

Mean :2020-02-23 06:56:04.97

3rd Qu.:2020-08-18 00:04:25.18

Max. :2021-02-17 15:42:27.68

AP02SDTM

Min. :2021-02-11 23:06:46.68

1st Qu.:2021-02-17 12:39:02.68

TRTEDTM

Min. :2022-02-12 04:55:58.68

1st Qu.:2022-02-17 18:28:14.68

Median :2022-07-17 05:19:26.68

Mean :2022-11-02 17:00:49.00

3rd Qu.:2023-08-02 12:16:13.68

Max. :2024-02-18 09:10:03.68

NA's :365

TRT01EDTM

Min. :2021-02-11 23:06:46.68

1st Qu.:2021-02-17 12:39:02.68

Median :2021-07-16 23:30:14.68

Mean :2021-11-02 11:11:37.00

3rd Qu.:2022-08-02 06:27:01.68

Max. :2023-02-18 03:20:51.68

NA's :365

TRT02EDTM

Min. :2022-02-12 04:55:58.68

1st Qu.:2022-02-17 18:28:14.68

Median :2022-07-17 05:19:26.68

Mean :2022-11-02 17:00:49.00

3rd Qu.:2023-08-02 12:16:13.68

Max. :2024-02-18 09:10:03.68

NA's :365

AP01EDTM

Min. :2021-02-11 23:06:46.68

1st Qu.:2021-02-17 12:39:02.68

Median :2021-07-16 23:30:14.68

Mean :2021-11-02 11:11:37.00

3rd Qu.:2022-08-02 06:27:01.68

Max. :2023-02-18 03:20:51.68

NA's :365

AP02EDTM

Min. :2022-02-12 04:55:58.68

1st Qu.:2022-02-17 18:28:14.68

Median :2021-07-16 23:30:14.68	Median :2022-07-17 05:19:26.68
Mean :2021-11-02 11:11:37.00	Mean :2022-11-02 17:00:49.00
3rd Qu.:2022-08-02 06:27:01.68	3rd Qu.:2023-08-02 12:16:13.68
Max. :2023-02-18 03:20:51.68	Max. :2024-02-18 09:10:03.68
NA's :365	NA's :365

EOSSTT	EOTSTT	EOSDT	EOSDY
COMPLETED :1035	COMPLETED :1035	Min. :2022-02-12	Min. : 369.0
DISCONTINUED: 600	DISCONTINUED: 600	1st Qu.:2022-02-17	1st Qu.: 865.0
ONGOING : 365	ONGOING : 365	Median :2022-07-17	Median :1096.0
		Mean :2022-11-02	Mean : 965.8
		3rd Qu.:2023-08-02	3rd Qu.:1096.0
		Max. :2024-02-18	Max. :1096.0
		NA's :365	NA's :365

DCSREAS	DTHDT	DTHCAUS
DEATH : 350	Min. :2022-02-14	ADVERSE EVENT : 130
ADVERSE EVENT : 70	1st Qu.:2022-03-01	DISEASE PROGRESSION: 100
PROTOCOL VIOLATION: 60	Median :2022-03-11	MISSING : 35
LACK OF EFFICACY : 35	Mean :2022-03-13	LOST TO FOLLOW UP : 30
PHYSICIAN DECISION: 35	3rd Qu.:2022-03-28	SUICIDE : 25
(Other) : 50	Max. :2022-04-10	(Other) : 30
NA's :1400	NA's :1650	NA's :1650

DTHCAT	LDDTHELD	LDDTHGR1	LSTALVDT
ADVERSE EVENT : 130	Min. : 1.0	<=30: 195	Min. :2022-02-14
OTHER : 120	1st Qu.:12.0	>30 : 155	1st Qu.:2022-03-15
PROGRESSIVE DISEASE: 100	Median :25.0	NA's:1650	Median :2022-08-07
NA's :1650	Mean :26.2		Mean :2022-11-23
	3rd Qu.:39.0		3rd Qu.:2023-08-23
	Max. :50.0		Max. :2024-03-07
	NA's :1650		NA's :365

DTHADY	ADTHAUT	study_duration_secs	ASEQ	TTESEQ
Min. : 399.0	No : 50	Min. :63113904	Min. :1.00	Min. :1.00
1st Qu.: 564.0	Yes : 235	1st Qu.:63113904	1st Qu.:1.75	1st Qu.:1.75
Median : 765.5	NA's:1715	Median :63113904	Median :2.50	Median :2.50
Mean : 762.4		Mean :63113904	Mean :2.50	Mean :2.50
3rd Qu.: 924.0		3rd Qu.:63113904	3rd Qu.:3.25	3rd Qu.:3.25
Max. :1122.0		Max. :63113904	Max. :4.00	Max. :4.00
NA's :1650			NA's :400	NA's :400

PARAM	PARAMCD	AVAL	AVALU
Duration of Confirmed Response:400	CRSD:400	Min. : 0.00	COUNT: 400
Event Free Survival :400	EFS :400	1st Qu.: 35.74	DAYS :1600
Overall Survival :400	OS :400	Median : 209.89	
Progression Free Survival :400	PFS :400	Mean : 395.45	
Total Number of Exacerbations :400	TNE :400	3rd Qu.: 531.73	

Max. :4708.68

ADTM	ADY	CNSR
Min. :2019-03-14 01:00:00	Min. : 0.0	Min. :0.000
1st Qu.:2020-09-24 02:00:00	1st Qu.: 211.0	1st Qu.:0.000
Median :2021-05-16 02:00:00	Median : 434.0	Median :0.000
Mean :2021-05-28 14:42:18	Mean : 460.8	Mean :0.307
3rd Qu.:2021-12-11 07:00:00	3rd Qu.: 678.2	3rd Qu.:1.000
Max. :2024-01-07 01:00:00	Max. :1095.0	Max. :1.000
NA's :400	NA's :400	

EVNTDESC	CNSDTDSC	lgTMATRSK
Length:2000	Length:2000	Min. : -7.3986
Class :character	Class :character	1st Qu.: -2.2568
Mode :character	Mode :character	Median : -1.4884
		Mean : -1.7128
		3rd Qu.: -0.8414
		Max. : 1.1114
		NA's :1600

## 2.2 Your first app

As is generally the case when you start a project, you should have an approximate idea of what you would like to achieve. In this case, the aim is to create an app that visualizes variables of three connected study data-sets.

## 2.3 Code structure

First, you want to define the project metadata. This can include the author name, the study name, the molecule name, etc. then, we have a section where we can define parameters for the app. This can be simple parameter values but they can also be short code snippets that would otherwise often be repeated throughout the application, e.g. preselected variables of interest.

After that, we define the app using the `init()` function. This function takes data, modules, and html input and returns a list (usually named `app`) containing the user interface (the `ui` object) and back end (the `server` object) of the application. In the final step we instantiate the app by calling `shinyApp(app$ui, app$server)`.

## 2.4 `init()`

The most crucial function of the `teal` package(s) is the `teal::init()` function, which is structured as follows:

```
init(  
  data,  
  modules,  
  title = NULL,  
  filter = list(),  
  header = tags$p("Add Title Here"),  
  footer = tags$p("Add Footer Here"),  
  id = character(0))
```

The `init()` function sets up a shiny app that consists of `teal` modules. Let's go through the arguments:

### **data**

In the `data` argument we define one or more data-frames for the application. If more than one data-frames are specified, they should be combined as a list, e.g. `data = list(ADSL, ADTR)`. For ADaM data-sets, the package `teal.data` provides helper functions with which the `data` argument of `init()` can be specified, — the `cdisc_data()` and the `cdisc_dataset()` functions. They allow the teal app to know the merge key variables of the data-sets. The `cdisc_data` function returns an S6 object.

**i** keys are prespecified variables in ADaM data to merge data-sets. Each type of data-set requires specific keys to be specified. The package `teal.data` automatically chooses the correct key variables based on the `dataname` for the following data-sets: ADSL, ADAE, ADEG, ADTTE, ADAETTE, ADCM, ADEX, ADLB, ADMH, ADQS, ADRS, ADSAFTTE, ADVS, ADDV, ADSUB, ADHY.

If you want to work with other ADaM data-sets you must specify the keys manually. ADTR is a Tumor Results Analysis data-set where there is one record (row) per subject. As of now, this is not part of the default `cdisc` keys in the `teal.data` package, so we would have to specify them manually:

```
ADTR <- random.cdisc.data::cadtr

cdisc_data(
  cdisc_dataset("ADSL", ADSL),
  cdisc_dataset("ADTR", ADTR, keys = c("STUDYID", "USUBJID", "PARAMCD", "AVISIT")))
```

Note that all keys have to be specified.

### **!** pre-processing

Generally, it is recommended to collect all data pre-processing steps in a separate R-script, which can then directly be applied to the `'cdisc_data()'` output. One such preprocessing steps could be the creation of a new variable in the ADSL data-set which splits patients into two age groups where patients younger than 40 are `AGEGR = 0` and patients older than 40 are `AGEGR = 1`.

```
# you would write this in a separate file directly, without the writeLines command.
writeLines(
  text = c("ADSL <- ADSL %>%
    dplyr::mutate(AGEGR = if_else(AGE < 40, 0, 1, NA_real_))"),
  con = "ADSL_preproc.R"
)
```

The resulting R file looks something like this:

```
ADSL <- ADSL %>% dplyr::mutate(AGEGR = if_else(AGE < 40, 0, 1, NA_real_))
```

```
ADSL_processed <- ADSL %>%
  cdisc_dataset("ADSL", .) %>%
  mutate_dataset(script = "ADSL_preproc.R")
# check if the new variable exists:
ADSL_processed$get_raw_data()$AGEGR
```

[illegible]

In a real world case we would not necessarily want to separately save the preprocessed ADSL in our environment. Instead, we would apply the preprocessing within the `data` argument of the `init()` function, e.g., like this:

```
app <- teal::init(data = cdisc_data(
  cdisc_dataset("ADSL", ADSL) %>%
    mutate_dataset(script = "ADSL_preproc.R"),
  cdisc_dataset("ADAE", ADAE),
  cdisc_dataset("ADTTE", ADTTE)
# <<additional dataset code>>
),
# <<additional init arguments code>>
```

### 2.4.1 modules

header

footer

id

Combining everything above, our `init()` function looks like this:

```

app <- teal::init(
  data = cdisc_data(
    cdisc_dataset("ADSL", ADSL) %>%
      mutate_dataset(script = "ADSL_preproc.R"),
    cdisc_dataset("ADAE", ADAE),
    cdisc_dataset("ADTTE", ADTTE)
  ),
  modules = modules(tm_variable_browser(label = "View Variables")),
  header = "My first application",
  footer = "footer"
)

```

## 2.5 Toy app

```

# data app
## ---- load packages data app ----
library(random.cdisc.data) # this package provides the data used
library(teal.data)
library(scda)
library(teal.modules.general)
library(sparkline)
library(teal)
library(tidyverse)

## ---- parameter data app ----
author <- "Stefan Thoma"
molecule <- "hexadromedar"

## ---- load data data app ----
ADSL <- random.cdisc.data::cads1
ADAE <- random.cdisc.data::cadae
ADTTE <- random.cdisc.data::cadtte

## ---- init data app ----
app <- teal::init(
  data = cdisc_data(
    cdisc_dataset("ADSL", ADSL) %>%

```




```
      mutate_dataset(script = "ADSL_preproc.R"),
      cdisc_dataset("ADAE", ADAE),
      cdisc_dataset("ADTTE", ADTTE)
    ),
    modules = modules(tm_variable_browser(label = "View Variables")),
    header = "My first application",
    footer = "footer"
  )

## ---- run data app ----
shinyApp(app$ui, app$server)
```

The output should look something like this:

## 2.6 Production app

# My first application



Add Footer Here

Plot:46689 Token:3641d145

Figure 2.1: Data App preview

## 3 efficacy

[http://docs.roche.com/#/agile-R/2022\\_01\\_28/teal/sample\\_\\_apps/sample-app-efficacy/](http://docs.roche.com/#/agile-R/2022_01_28/teal/sample__apps/sample-app-efficacy/)

## 4 Summary

In summary, this book has no content whatsoever.

`1 + 1`

[1] 2

## References